Been Lukas B, Suurmeijer Albert J H, Cobben David C P, Jager Pieter L, Hoekstra Harald J, Elsinga Philip H
PET Center, Groningen University Hospital, Groningen, RB, The Netherlands.
Eur J Nucl Med Mol Imaging. 2004 Dec;31(12):1659-72. doi: 10.1007/s00259-004-1687-6.
In recent years, [18F]-fluoro-3'-deoxy-3'-L: -fluorothymidine ([18F]FLT) has been developed as a proliferation tracer. Imaging and measurement of proliferation with PET could provide us with a non-invasive staging tool and a tool to monitor the response to anticancer treatment. In this review, the basis of [18F]FLT as a proliferation tracer is discussed. Furthermore, an overview of the current status of [18F]FLT-PET research is given. The results of this research show that although [18F]FLT is a tracer that visualises cellular proliferation, it also has certain limitations. In comparison with the most widely used PET tracer, [18F]FDG, [18F]FLT uptake is lower in most cases. Furthermore, [18F]FLT uptake does not always reflect the tumour cell proliferation rate, for example during or shortly after certain chemotherapy regimens. The opportunities provided by, and the limitations of, [18F]FLT as a proliferation tracer are addressed in this review, and directions are given for further research, taking into account the strong and weak points of the new tracer.
近年来，[18F] - 氟 - 3'-脱氧 - 3'-L - 氟胸腺嘧啶核苷（[18F]FLT）已被开发为一种增殖示踪剂。利用正电子发射断层扫描（PET）对增殖进行成像和测量可为我们提供一种非侵入性分期工具以及监测抗癌治疗反应的工具。在本综述中，将讨论[18F]FLT作为增殖示踪剂的基础。此外，还将概述[18F]FLT - PET研究的现状。该研究结果表明，尽管[18F]FLT是一种可显示细胞增殖的示踪剂，但它也存在一定局限性。与使用最广泛的PET示踪剂[18F]FDG相比，在大多数情况下，[18F]FLT的摄取较低。此外，[18F]FLT摄取并不总是反映肿瘤细胞增殖率，例如在某些化疗方案期间或之后不久。本综述探讨了[18F]FLT作为增殖示踪剂所带来的机遇和局限性，并考虑到这种新型示踪剂的优缺点，给出了进一步研究的方向。
